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Abstract 
A single Heat Shock Factor (HSF), mediating the heat shock response, exists from yeast to 
Drosophila, while several related HSFs have been found in mammals. This raises the question 
of the specific or redundant functions of the different members of the HSF family and in 
particular of HSF1 and HSF2 which are both ubiquitously expressed. Using immortalized 
mouse embryonic fibroblasts (iMEFs) derived form either wild-type, Hsf1-/-, Hsf2-/- or double-
mutant mice, we observed distinctive behaviors of these mutants with respect to proteasome 
inhibition. This proteotoxic stress reduces to the same extent the viability of Hsf1-/- and Hsf2-/-
deficient cells, but through different underlying mechanisms. Contrary to Hsf2-/- cells, Hsf1-/- 
cells are unable to induce prosurvival Heat Shock Protein (HSP) expression. Conversely, 
proteasome activity is lower in Hsf2-/- cells and the expression of some proteasome subunits, 
such as Psmb5 and gankyrin is decreased. Since gankyrin is an oncoprotein involved in p53 
degradation, we analyzed the status of p53 in HSF-deficient iMEFs and observed that it was 
strongly stabilized in Hsf2-/- cells. This study points a new role for HSF2 in the regulation of 
protein degradation and suggests that pan-HSF inhibitors could be valuable tools to reduce 
chemoresistance to proteasome inhibition observed in cancer therapy.  
 
Introduction 
Vertebrate genome contains 3 to 5 members of the Heat Shock Transcription Factor (HSF) 
family (for review see Pirkkala et al., 2001; Akerfelt et al., 2007). Within this family, HSF1 
and HSF2 possess close related DNA-binding domains but they exhibit some slight 
differences in Heat Shock Element (HSE) recognition (Kroeger and Morimoto, 1994; 
Yamamoto et al., 2009), suggesting that both factors control different set of genes. HSF1 
represents the archetypal stress transcription factor, rapidly activated by a large variety of 
proteotoxic stimuli. It regulates the stress inducible expression of Heat Shock Proteins (HSPs) 
but also controls numerous other genes as demonstrated by transcriptome analysis (Trinklein 
et al., 2004). Recently, it was shown that HSF1, by favouring cellular adaptation and survival 
in response to environmental stress, also enhances oncogenic transformation (Dai et al., 
2007). In comparison to HSF1, HSF2 is a less efficient transcriptional activator and appears to 
be differently responsive to stimuli (Sistonen et al., 1992). However, inhibition of the 
proteasome activates both, HSF1 and HSF2 (Kawazoe et al., 1998). Proteasome inhibition 
leads to the accumulation of misfolded proteins and consequently induces expression of all 
the major HSPs (Bush et al., 1997), but Pirkkala and coworkers (Pirkkala et al., 2000), clearly 
showed that HSF1, but not HSF2, plays a key role in this induction. Nevertheless, to add to 
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the complexity of this proteotoxic response, our group showed that a HSF1/HSF2 
heterocomplex was present on the promoter of the chaperone gene Clusterin, following 
proteasome inhibition (Loison et al., 2006). The existence of HSF1/HSF2 heterotrimer was 
recently confirmed (Sandqvist et al., 2009) and it was demonstrated that HSF2 can act as a 
modulator of HSF1 activity in response to proteotoxic insults (Ostling et al., 2007). Hence, 
the respective role of HSF1 and HSF2 remains unclear when cells are exposed to proteasome 
inhibitors. 
The proteasome/ubiquitin system constitutes the major pathway for regulated 
degradation of intracellular proteins. The proteasome holoenzyme is a large multi-subunit 
complex composed of a 20S proteolytic core particle associated with one or two 19S 
regulatory particles (Pickart and Cohen, 2004). The 20S core particle is a cylindrical structure 
made up of four heteromeric rings. The two outer rings are composed of seven different α 
subunits (named α1 to α7), whereas the two inner rings are composed of seven different β 
subunits (β1-β7) and formed the catalytic chamber. Although these subunits are evolutionary 
related and similarly conserved, only β1, β2 and β5 possess proteolytic properties. The 19S 
regulatory particle comprises approximately eighteen distinct subunits that form a lid 
controlling the access to the catalytic core particle. Proteins destined to be degraded by 
proteasome must be conjugated to multi-ubiquitin chain for recognition by the 19S regulatory 
particle. Dysfunction of the proteasome pathway can lead to many disorders, including 
cancers and neurodegenerative diseases (Paul, 2008). Proteasome is crucial for the regulation 
of cell cycle and apoptosis and its specific inhibition by molecules has emerged as a 
promising strategy to treat cancers (Nencioni et al., 2007). For example, bortezomib (also 
known as PS-341 or Velcade®) is the first proteasome inhibitor used in the treatment of 
multiple myeloma (Twombly, 2003). In addition, proteasome inhibition may modulate many 
other transcriptional events (Muratani and Tansey, 2003) and the activity of stress-related 
transcription factors, such as p53 and HSFs.  
To determine the contribution of HSF2 versus HSF1 in cell response to proteasome 
inhibitors, we used immortalized Mouse Embryonic Fibroblasts (iMEFs) derived from wild 
type (WT), Hsf1 and/or Hsf2 knock-out (KO) mice (McMillan et al., 1998; McMillan et al., 
2002). We found that both factors are essential for cell viability but have distinct actions: as 
previously shown, HSF1 is required in the induction of pro-survival HSP expression and in 
contrast, HSF2 is involved in the regulation of proteasome subunit expression. 
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Results  
Proteasome inhibition is severely toxic for HSF1 and/or HSF2-deficient cells. 
To determine the specific contribution of HSF1 and HSF2 to the cellular response to 
proteasome inhibition, we first examined the cytotoxic effect of two proteasome inhibitors: 
the peptide aldehyde MG132, a reversible inhibitor and the peptide epoxyketone Epoxomicin, 
an irreversible inhibitor. To assess viability of iMEFs cells, we utilized the quantitative 
colorimetric MTT test as cytotoxicity assay and we established concentration-effect curves 
after a 16 h treatment. With high concentrations of MG132 (830 nM) or Epoxomicin (250 
nM) Hsf1-/-, Hsf2-/- or Hsf1-/- & Hsf2-/- iMEFs were significantly more sensitive to these 
proteasome inhibitors than WT cells (Student’s t-test, p < 0.05 and p<0.001 respectively) 
(Fig. 1A and 1B, respectively). By comparison, we treated cells with Thapsigargin that 
induces a proteotoxic stress specific to the reticulum endoplasmic without affecting 
proteasome activity and without activating HSF. In contrast to proteasome inhibition, 
Thapsigargin treatment had the same effect on the four cell lines. These data clearly showed 
that the higher sensitivity of HSF1- and HSF2-deficient cells was specific to proteasome 
switch off and was not a direct consequence of a general alteration of stress response in these 
KO cells (Fig. 1 C). 
To evaluate whether the decline of MTT values after proteasome inhibition was due to 
an antiproliferative or a cytotoxic effect, we conducted a flow cytometric analysis of cellular 
viability. The WT or HSF-deficient iMEFs were treated for 16 h with 1 µM of MG132, and 
then apoptotic levels were determined by staining with annexin V-fluorescein isothiocyanate 
(FITC) and 7-aminoactinomycin D (7-AAD) (Fig. 1 D and supplemental Fig. S1). Mortality 
of all the cell lines was increased in MG132 treated samples, and apoptosis level in HSF-
deficient cells was found 2 fold higher compared to WT cells. These data revealed that both 
factors, HSF1 and HSF2, are critical for cell survival when proteasome is inhibited. 
 
HSP induction is differently affected in Hsf1-/- and Hsf2-/- iMEFs 
HSPs are important chaperones induced by proteotoxic stress where they contribute to 
cell death resistance (Beer HM, 2005). Thus we analysed the inducible expression of two 
HSPs: HSP70 and HSP25. Messenger RNA levels of Hsp25 and Hsp70 in WT, HSF1 and/or 
HSF2-deficient iMEFs were compared in absence or presence of MG132 (Fig. 2A and 2B). 
After MG132 exposure, only iMEFs expressing HSF1 (either WT or Hsf2-/-) were able to 
exhibit a strong induced expression of both chaperones, whereas iMEFs deficient in HSF1 
(Hsf1-/- and Hsf1-/- & Hsf2-/-) did not. Those data indicated that expression of inducible Hsp70 
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and Hsp25 is highly dependent on the presence of HSF1. These results were confirmed by 
immunoblot (Fig. 2C), HSP25 and HSP70 are strongly increased in WT cells but not in 
HSF1-depleted cells (Hsf1-/- and Hsf1-/- & Hsf2-/-). Moreover, HSF2-depleted cells display 
higher levels of HSP25 and HSP70 than those observed in WT iMEFs – wich could be 
explained by a lower level of protein degradation and thus an increase in protein’s half-life in 
those Hsf2-/- cell lines. Hence, it was unlikely that the high sensitivity of Hsf2-/- cells to 
proteasome inhibition could be explained by the lack of HSPs. This suggested that another 
mechanism should be involved.  
 
Proteasome activity is decreased in Hsf2-/- iMEFs 
To test this possibility that proteasome function would be natively affected, an in vitro 
assay based on the measurement of the chymotrypsin-like activity of proteasome present in 
crude protein extract was first used. Secondly, the proteasome activity at the cellular level was 
evaluated, by setting up an assay based on the degradation of a proteasome-targeted protein.  
A fluorescent proteasome substrate (Z-LLVY-AMC) was incubated with cellular 
extracts from the different iMEFs cell lines. This peptide was hydrolyzed by chymotrypsin-
like activity of proteasome releasing the fluorophore that could be assessed with a 
spectrofluorimeter (Fig. 3A). Hsf2-/- and Hsf1-/- & Hsf2-/- cellular extracts contain a lower 
amount of active proteasome (0.36 +/- 0.11 and 0.21 +/- 0.04, respectively) compared to WT 
iMEFs (0.96 +/- 0.20). Decrease of proteasome activity measured in Hsf1-/- cells (0.63 +/- 
0.14) was less striking but still significant. To ascertain that measured fluorescence was due to 
proteasome activity, crude extracts were incubated with the peptide and 10 µM of MG132 and 
no fluorescence could be measured, indicating that this inhibitor clearly abolished the 
previously assessed activity. 
To confirm in vivo this observation at the cellular level, expression vector coding for 
the fusion protein uncleavable Ubiquitin-Green Fluorescent Protein (Ubi-GFP) was 
transfected in iMEFs. The mutated non cleavable ubiquitin moiety within the fusion protein 
serves as template to poly-ubiquitination, which is addressed to proteasome for degradation. 
Thus, intracellular accumulation of the unstable Ubi-GFP requires partial or total inhibition of 
proteasome/ubiquitin system. Ubi-GFP expression vector was co-transfected with a plasmid 
coding for EGFP, as internal control to evaluate the difference of transfection efficiencies 
between the iMEFs cell lines. Then, the protein levels of GFP were probed by 
immunoblotting, using the same antibody (Fig. 3B). In all cell lines (except the double knock-
out iMEFs), the EGFP control is highly expressed, demonstrating that the transfections were 
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equally efficient. We found that in WT and Hsf1-/- cells, the Ubi-GFP specific bands were not 
visible in untreated cells while it became slightly detectable when cells were incubated with 1 
µM of MG132. These data showed that Ubi-GFP was efficiently targeted to proteasomal 
degradation and demonstrated that exposure to 1 µM MG132 could not block totally the 
intracellular proteasome activity. By contrast, Ubi-GFP was significantly more stable in cells 
deficient in HSF2 (Hsf2-/- and Hsf1-/- & Hsf2-/-), especially after MG132 treatment (Fig. 3B, 
lanes 6 and 8, respectively). This indicated that HSF2-deficient cells exhibited a reduced 
proteasome activity either due to functional defect or reduced amount of the proteasome 
machinery in comparison to WT.  
 
Partial but significant depletion of Ubiquitin-proteasome machinery in Hsf2-/- iMEFs 
To determine whether the decrease of proteasome activity was linked to reduced level 
of proteasome subunit expression, 10 subunits were selected (5 located in the 20S particle and 
5 located in the 19S particle – Table 1) based on the work of Kruger’s team about proteasome 
expression in response to proteasome inhibition (Meiners et al., 2003) and the level of 
transcripts was analyzed by real time PCR analysis. The expression level of two ubiquitin 
genes (Ubb and Ubc) was also analyzed. As summarized in Table 1, a decreased expression 
was observed in absence of HSF1 for some proteasome subunits and for Ubb and Ubc but at a 
lower level than observed in HSF2-deficient cells. In fact, the level of the majority of the 20S 
and 19S subunits likewise the two ubiquitin genes decreased by a factor 2 or 3 fold in HSF2-
deficient cells.  However, mRNA levels of two subunits, Psmb4 and Psmc5 were unchanged 
in HSF-deleted cells compared to WT, suggesting that all constitutive subunits are not 
regulated in the same way. In addition, it is interesting to note that the level of the β5 catalytic 
subunit (Psmb5) was significantly lower in Hsf2-/- and Hsf1-/- & Hsf2-/- cells (Table 1 and Fig. 
4A), which is consistent with the decrease of proteasome activity measured in these cells (Fig. 
3). To ascertain that this decrease of expression was due to the lack of HSF2, we stably 
transfected Hsf2-/- iMEFs with a plasmid coding for HSF2 or a control vector (Fig. 4C and 
supplemental Fig. S2). Reintroduction of HSF2 allowed a rescue of Psmb5 expression which 
was 2-3 fold higher in transfected cells with Hsf2 vector in comparison to empty vector.  
 
Increased stability of p53 in HSF2-depleted cells 
As shown in Fig. 4B, Psmd10 or gankyrin, an oncogene overexpressed in human 
hepatic cancers (Higashitsuji et al., 2000) was 2-4 fold down-regulated in HSF2-deficient 
iMEFs and its expression was totally rescued when cells were transfected with Hsf2 vector 
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(Fig. 4D). As gankyrin is also known to interact with the MDM2 ubiquitin ligase and to play a 
pivotal role in controlling the level of p53 by proteasomal degradation (Higashitsuji et al., 
2005), we wanted to determine whether the lower level of gankyrin affects intracellular p53 
concentration. Using untreated cells, in immunoblot assay, endogenous p53 was hardly visible 
in WT and Hsf1-/- iMEFs, whereas it was dramatically increased in both Hsf2-/- and in Hsf1-/- 
& Hsf2-/- iMEFs (Fig. 5A). Real time PCR analysis revealed that there was no significant 
increased level of p53 transcripts in cell lines which exhibited higher p53 protein content, 
suggesting that this p53 up-regulation in HSF2-deficient cells was due to protein stabilization 
(Fig. 5B). Finally, a pulse-chase experiment using p53 antibody was performed to assess p53 
half-life in our model. As shown in Fig. 5C, endogenous p53 in WT iMEFs exhibited a very 
short half-life (less than 1 h). In Hsf1-/- iMEFs p53 half-life was slightly longer than in WT 
cells as previously described (Jin et al., 2009). P53 was yet detected after 2 hours of chase. 
This result was in accordance with the decrease of proteasome activity, observed in HSF1-
deleted cells. In sharp contrast with this modest increased stability, p53 was dramatically 
stabilized to a half-life of more than 9 h, in Hsf2-/- cells. To confirm this stabilization, p53 
immunoblotting was performed in primary MEF from WT, Hsf1-/- and/or Hsf2-/- mice. In 
those cells, the basal endogenous p53 was not detectable (Fig. 5D). In contrast, when cells 
were treated with 1 µM of MG132, p53 was slightly increased in WT and Hsf1-/- MEFs 
whereas a strong accumulation was detectable in Hsf2-/- and Hsf1-/- & Hsf2-/- MEFs. All 
together our data suggest that proteasome and gankyrin down-regulations in Hsf2-/- cells are 
accompanied by stabilization of the short-lived protein p53.  
 
Discussion 
Proteasome inhibition causes an accumulation of altered proteins, generating a 
proteotoxic stress, which was shown to simultaneously activate both HSF1 and HSF2 
(Kawazoe et al., 1998). Nevertheless the respective roles of HSF1 and HSF2 remained 
unclear. We took advantage of genetically modified cells to further clarify the specific 
function of each factor in the cellular response to such a stress. We found that HSF1 and 
HSF2 were both critical for the resistance to proteasome inhibition. However, HSF1 and 
HSF2 are involved in different mechanisms.  
HSF1 deficiency dramatically prevented the induced expression of Hsp25 and Hsp70 
after proteotoxic stress. This was in agreement with previous works showing that HSF1 is the 
major factor involved in proteotoxic response and that it could not be compensated by HSF2 
alone (Pirkkala et al., 2000). As HSP25 and HSP70 promote cellular survival by preventing 
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protein aggregation, facilitating refolding and directly inhibiting apoptotic signalling (Beere et 
al., 2000; Bruey et al., 2000), Hsf1-/- cells lacked an important protective mechanism which 
could explain the observed reduction in cell survival. In contrast to Hsf1 deletion, Hsf2 
deletion did not prevent induction of Hsp25 and Hsp70 expression. Thus, the high expression 
of protective HSP in Hsf2-/- iMEFs led us to conclude that HSF2 and cell sensitivity to 
proteasome inhibition were linked by a different mechanism. According to this hypothesis, we 
were interested to proteasome subunit expression and found that it was particularly affected in 
Hsf2-/- cells. 
Little is known about the regulation of basal expression of mammalian proteasome 
subunits. Recently, one study suggested that each type of proteasome subunits could be 
regulated by common unknown transcription factors (Sato et al., 2009). It was found that 
inactivation of HSF1 does not alter proteasome expression (Taylor et al., 2005) and our data 
are in accordance with this report as we show that Hsf1-/- iMEFs exhibit a slight but not 
significant decrease of proteasome subunit expression. However, this slight decrease could be 
explained by interdependence between HSF2 and HSF1 (Loison et al., 2006; Sandqvist et al., 
2009). Thus, one could hypothesize that the lack of HSF1 would affect HSF2 binding and 
consequently reduce HSF2 activity.  
Currently, we do not know if HSF2 regulates proteasome subunit expression indirectly 
or by direct binding to the promoters of the corresponding genes. By in silico analysis we 
searched for the presence of HSE, within genes encoding proteasome subunits and found that 
the majority of those genes possess putative degenerated HSEs. For example, the gankyrin 
gene contains a conserved HSE into its first intron. This sequence was able to bind HSF in 
electrophoretic mobility shift assay, but we hardly detected in vivo HSF2 binding by 
chromatin immunoprecipitation assay (data not shown). The difficulty of detecting HSF2 
bound to gankyrin HSE could be explained by the fact that this interaction could be very 
transient. Recently, HSF2 was found to ephemerally bind to Hsp promoters during mitosis 
and that interaction favoured the basal expression of Hsps. (Xing et al., 2005; Wilkerson et 
al., 2007). So, it is possible that the role of HSF2 in bookmarking that maintains an open 
chromatin at the promoters of certain genes entails the constitutive expression level of 
proteasome subunits. To test this hypothesis, Formaldehyde Assisted Isolation of Regulated 
Element assay was performed (supplemental Fig. S3) and showed that chromatin was more 
compacted at gankyrin transcription start site in HSF-deficient cells than in WT cells. 
However, another mechanism described in yeast could be implicated. An indirect 
transcriptional network involving HSF and RPN4 was demonstrated (Hahn et al., 2006). This 
 9
latter protein corresponds to the main transcription factor implied in the expression of yeast 
proteasome subunits but no mammalian homolog has been described to date.  
The decreased expression of proteasome subunits has consequence for cell physiology. 
Alteration of proteasome activity has been implicated in the pathogenesis of cancers 
(Schwartz and Ciechanover, 1999) and in some cells, a clear relationship has been established 
between increased expression of proteasome and proliferation or resistance to apoptosis 
(Fuchs et al., 2008). We found that decrease of catalytic subunit β5 and gankyrin in HSF2-
depleted cells was accompanied by p53 stabilization. It would be interesting to determine 
whether re-introduction of gankyrin in Hsf2-/- iMEF could restore the level of p53, knowing 
that it was already demonstrated that gankyrin overexpression accelerates the degradation of 
p53 in various cell models, including MEF (Higashitsuji et al., 2005). Mivechi’s group 
described a mechanism linking HSF1-deficiency and p53 stabilization (Homma et al., 2007; 
Jin et al., 2009). Our study confirms a role for HSF1 in the regulation of p53 with a slight 
stabilization of this protein in pulse chase experiment compared to WT cells. However, our 
work completes the mechanism by introducing HSF2 as a new actor. The iMEFs used in this 
study have been immortalized with T antigen of SV40 virus that is known to bind to p53 and 
blocks its transcriptional activity (Pipas and Levine, 2001) which could permit its stabilization 
in our model. However our results (p53 stabilization) were confirmed by p53 immunoblot in 
primary MEFs. Furthermore, it was found that SV40 transformation does not affect the 
protein control machinery (Cantalupo et al., 2009), which emphasizes that the decrease of 
ubiquitin-proteasome system expression is related to the loss of Hsf2 gene confirmed by 
HSF2 rescue.  
Development of inhibitors of both HSF1 and HSF2 could be a valuable approach to 
increase effectiveness of cancer therapy. By blocking HSF1, it is possible to alter the adaptive 
transcriptional response that allows the expression of anti-apoptotic chaperones (Zaarur et al., 
2006). Therapeutic use of proteasome inhibitors remains limited because of the selection of 
resistant cells. It was found that bortezomib-adapted cells showed increased expression of β5 
and β2 proteasome subunits (Oerlemans et al., 2008; Rückrich et al., 2009), and we found that 
one of these subunits was down-expressed in absence of HSF2. Moreover, by blocking HSF2, 
the level of intracellular proteasome is expected to decrease and potentially to increase the 
sensitivity to proteasome inhibition, even in resistant clones. Recently, a close correlation was 
demonstrated between expression levels of proteasome subunits, their enzymatic activity and 
the sensitivity of cells to proteasome inhibitor (Busse et al., 2008). Finally, a decrease of 
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gankyrin level in Hsf2-blocked cells would permit overexpression of p53 that will in turn 
participate in the apoptosis of treated cells. 
In conclusion, our work in iMEFs brought new insights in the respective roles of 
HSF1 and HSF2, the most abundantly expressed HSF in organisms. Beyond these 
fundamental interests in a better understanding of transcription factor, the data presented here 
confirm that HSF1 and now HSF2 could be targeted with benefits in cancer therapy. 
 
Materials and methods 
Cell culture  
Mouse Embryonic Fibroblasts Wild Type (WT), deleted for HSF1 (Hsf1-/-), HSF2 (Hsf2-/-) or 
both genes (Hsf1-/- & Hsf2-/-) were isolated from KO mice (McMillan et al., 1998 ; McMillan 
et al., 2002) and were immortalized using SV40 T antigen  by  Dr V. Mezger (UMR CNRS 
7216, Paris, France). Cells were maintained in DMEM 4500 mg/L glucose (Gibco, CA, USA) 
supplemented with 10 % Fetal Bovine Serum (Biowest, France), 4 mM L-glutamine, Non 
Essential Amino-Acids and 100 Units/mL penicillin, 100 mg/mL streptomycin (Gibco, CA, 
USA). All cells were grown at 37°C under 5 % CO2. 
For rescue experiments Hsf2-/- iMEFs were stably transfected with plasmid coding for Hsf2α 
and HSF2 expression was confirm by RT-PCR and HSF2 immunoblotting in each selected 
clone (supplemental Fig. S2). 
 
Plasmid constructs and transfection 
An ubiquitin tagged green fluorescent protein (GFP) was previously used to quantify 
ubiquitin-proteasome dependent proteolysis in living cells (Dantuma et al., 2000). For this 
purpose, the DNA fragment from the pDG268 plasmid (kindly provided by Dr D. Gray, 
university of Ottawa, Canada), encoding an ubiquitin-EGFP fusion protein (Tsirigotis et al., 
2001), was transferred into pCDNA3 expression vector (Invitrogen Life science, CA, USA). 
Then, the carboxy-terminal glycine in ubiquitin was converted into a valine using the site 
directed mutagenesis kit QuickChange (Stratagene, CA, USA), to block cleavage of the 
ubiquitin moiety by cellular de-ubiquitinases and thus render the entire fusion prone to 
degradation by the ubiquitin-proteasome system. The vector coding for non cleavable 
ubiquitin fused to GFP (Ubi-GFP) was co-transfected with a plasmid coding for EGFP 
(pEGFP-C3, Clontech, CA, USA), as internal control of transfection efficiency. All 
transfections were performed with JetPEI (Polyplus Transfection, France), according to 
manufacturer’s instructions. Cells were harvested after 24 h of transient expression and 7 h of 
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treatment with DMSO or 1 µM of MG132 (Biomol, PA, USA). Relative quantity of these two 
GFP proteins was assessed by immunoblotting using anti-GFP antibodies (Invitrogen Life 
Science, CA, USA). 
 
Cell toxicity assay (MTT assay) 
WT, Hsf1-/-, Hsf2-/- and Hsf1-/- & Hsf2-/- iMEFs were spread in 96 wells-plate and were treated 
with increasing doses of proteasome inhibitors Epoxomicin (Sigma Aldrich, MO, USA), 
MG132 (Biomol, PA, USA), or with Thapsigargin (Sigma Aldrich, MO, USA), an inductor of 
endoplasmic reticulum stress. Cells were treated at the indicated concentration for 16 h. 
Following treatment, MTT [1-(4,5-Dimethylthiazol-2-yl)-3,5-diphenylformazan] (Sigma 
Aldrich, MO, USA) was added to cells at final concentration of 0.5 mg/ml. Cells were 
incubated for 3 h at 37°C under 5 % CO2. The medium was then discarded and formazan 
crystals were dissolved in 100 µl of isopropanol with 0.1 % SDS and 0.05 N HCl for 1 h at 
obscurity. Absorbance was read at 570 nm and results were expressed as percentage of 
untreated cells. 
 
Real Time PCR analysis 
One million cells for each iMEFs lines was plated into 10 cm plate and harvested after 24 h of 
culture. Total RNAs were extracted with Trizol reagent (Invitrogen Life Science, CA USA) 
according to the manufacturer’s procedure. Then 5 µg of RNA were retrotranscribed using M-
MLV RT (Invitrogen Life Science, CA USA). Real time PCR was performed using 12.5 ng of 
cDNA, 300 nM of primers (referred to supplemental data) and 1X SybrGreen, on 
MiniOpticon Real Time PCR (Bio-Rad, CA, USA). Amplification of each studied gene was 
normalized using amplification of three housekeeping genes Gapdh (Glyceraldehyde-3-
phosphate dehydrogenase), Hprt1 (Hypoxanthine guanine phosphoribosyl transferase 1) and 
Tbp (TATA box binding protein). Data were analysed using qBase software (Hellemans et 
al., 2007). 
 
Measurement of proteasome activity 
Proteasome activity was measured in accordance with the protocol described by Kisselev and 
Goldberg (Kisselev and Goldberg, 2005). Briefly, cells were harvested in a lysis buffer that 
maintained 26S proteasome integrity. After incubation on ice during 45 min, the cytosols 
were squeezed out by centrifugation at 14000 rpm at 4°C for 15 min. 15 µg of proteins were 
loaded on opaque white 96 well-plates. Volume was adjusted at 90 µl with 26S proteasome 
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assay buffer. Thereafter, 10 µl of Z-LLVY-AMC (Calbiochem, England) at 1 mM stock 
solution was added and plate was incubated at 37°C. Fluorescence was measured after 15 min 
and 30 min using a fluorimeter (Dynatech Laboratories, VA, USA) with excitation at 365 nm 
wavelength and emission at 450 nm wavelength. 
 
Protein extracts and immunoblot analyses 
Cells extracts were prepared using osmotic shock methods like previously described (Loison 
et al., 2006). Protein extracts were separated on polyacrylamide gel and transferred to 
nitrocellulose membrane (Amersham Bioscience, England). Anti-Hsp25 (sc-1084), anti-
Hsp70 (SPA-810), anti-β-actin (A-1978) antibodies were purchased from Santa Cruz 
Biotechnology (CA, USA), Stressgen (MI, USA) and Sigma Aldrich (MO, USA) 
respectively. Anti-p53 antibody was a gift from Dr T. Soussi, Université Pierre et Marie 
Curie, Paris, France.  
 
Pulse-Chase Assays 
Wild type, Hsf1-/- and Hsf2-/- iMEFs were washed with PBS and preincubated for 30 min with 
methionine- and leucine-free DMEM, containing 10 % dialyzed Fetal Bovine Serum and 4 
mM glutamine. Cells were labeled for 1 h 30 in the same medium with 10 µCi/ml of L-
[35S]methionine (PerkinElmer, France), and chased in complete media. At various times after 
termination of labeling, cells were isolated in PBS 0.5% Triton X-100 supplemented by 
protease inhibitors (Roche Applied Science, France) and incubated 30 min on ice. Proteins 
were immunoprecipitated overnight at 4°C with 5 µg of monoclonal anti-p53 antibody in PBS 
supplemented with NaCl 600nM, Triton X-100 4% and protease inhibitors (Roche Applied 
Science, France). Immune complexes recovered by protein-G Sepharose were washed three 
times with PBS supplemented with Triton X-100 1% and NaCl 150 mM. Immune complexes 
were electrophoretically separated on SDS-PAGE gels. Gels were fixed and dried and 
subjected to autoradiography. Corresponding lysates (lysates 35S) were loaded as control for 
equal amount of proteins, as well as equal incorporation of 35S.  
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Figures 
 
 
Fig. 1: Increased vulnerability to proteasome inhibition in HSF-deficient cells. Dose-
response curves for cell viability assessment by MTT assay were prepared using immortalized 
Mouse Embryonic Fibroblasts (iMEFs) exposed to proteasome inhibitors (A, MG132 and B, 
Epoxomicin) or endoplasmic reticulum stressor (C, Thapsigargin). WT (black diamond), 
Hsf1-/- (white square), Hsf2-/- (white triangle) and Hsf1-/- & Hsf2-/- (white circle) iMEFs were 
incubated for 16 h with DMSO (Cont) or indicated concentrations of the drugs before being 
subjected to MTT assay.  Results are expressed in percentage of survival compared to DMSO 
control (Student’s test: each KO cell compared to WT cells. * p<0.05, *** p<0.001). To 
confirm that decrease of survival was due to apoptosis, cells were treated with 1 µM of 
MG132 for 16h and apoptosis was assessed by flow cytometry using annexin V-FITC and 7-
AAD (D). Results were expressed in percentage of cell death for DMSO (cont) and MG132 
treated cells. Data are the means for three to four independent experiments +/- SEM.. 
 
 
 
 19
 
Fig. 2: HSF dependent response of Hsp25 and Hsp70 to proteasome inhibition. WT, 
Hsf1-/-, Hsf2-/- and Hsf1-/- & Hsf2-/- iMEFs were treated with DMSO (cont) or with 1 µM of 
MG132 for 10 h. Hsp70 (A) and Hsp25 (B) transcript levels were measured by real time PCR. 
Expression data were normalized by reference genes (see materials and methods) and 
analyzed with qBase software. Results were expressed in fold induction, normalized to 
DMSO sample of each cell line. Data are the means of three independent experiments +/- SD. 
(C) Corresponding immunoblot analysis of HSP70 and HSP25 expression in response to 1 
µM of MG132 for 10h in WT, Hsf1-/-, Hsf2-/- and Hsf1-/- & Hsf2-/- iMEFs. β-actin served as 
loading control.  
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Fig. 3: Proteasome catalytic activity in Hsf-deficient cells. (A) In vitro assay using 15 µg of 
protein extracts from WT, Hsf1-/-, Hsf2-/- and Hsf1-/- & Hsf2-/- iMEFs incubated with 100 µM 
of peptide coupled to a fluorophore (Z-LLVY-AMC) in presence of DMSO (cont) or with 10 
µM of MG132. The fluorescence was read after peptide cleavage by the proteasome’s 
chymotrypsin-like activity. The relative catalytic activity was expressed in fluorescence 
(Arbitrary Unit) per minute per microgram of proteins (Fluo/min/µg of prot). Data are the 
means for three independent experiments +/- SD (Student’s Test compare to WT cells. * 
p<0.05, *** p<0.001). (B). In vivo assay: plasmid coding for the fusion protein Ubiquitin-
GFP (Ubi-GFP) was co-transfected with a plasmid coding for EGFP used as transfection 
efficiency control. Ubiquitin part of the fusion protein serves as template for ubiquitination, 
rending the protein labile. Cells were treated with DMSO (Cont) or with 1 µM of MG132 for 
7 h and stabilization of Ubi-GFP protein was assessed by anti-GFP immunoblot. 
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  Proteasome subunit 
iMEF 
WT +/- SD
iMEF 
Hsf1-/- +/- SD
iMEF 
Hsf2-/-  
+/- 
SD 
iMEF 
Hsf1-/- & 
Hsf2-/- 
+/- 
SD 
Psma1 1,00 0,603 0,68 0,409 0,38 0,113 0,25 0,077
Psma5 1,00 0,909 0,98 0,948 0,57 0,503 0,72 0,518
Psmb2 1,00 0,408 0,69 0,252 0,46 0,189 0,38 0,179
Psmb4 1,00 0,443 1,31 0,303 0,78 0,164 0,98 0,237
Particle 
20S 
Psmb5 1,00 0,32 1,25 0,43 0,50 0,17 0,27 0,08 
Psmc4 1,00 0,377 0,95 0,727 0,41 0,151 0,23 0,086
Psmc5 1,00 0,354 1,09 0,214 1,21 0,256 1,28 0,329
Psmd3 1,00 0,586 1,00 0,515 0,66 0,273 0,48 0,294
Psmd4 1,00 0,328 1,03 0,243 0,79 0,238 0,82 0,273
Particle 
19S 
Psmd10 1,00 0,252 0,51 0,287 0,31 0,058 0,20 0,052
Ubb 1,00 0,352 0,66 0,211 0,35 0,171 0,30 0,124Ubiquitin 
Ubc 1,00 0,658 0,37 0,138 0,23 0,113 0,14 0,066
 
Table 1: Transcript levels of proteasome subunits and ubiquitin in iMEFs WT and HSF-
deficient. RNA level of five subunits of 20S particle, five subunits of the 19S particle and 
Ubiquitin B and C were measured by real time PCR and normalized using three reference 
genes Gapdh, Hprt1 and Tbp. Results are expressed as relative value to WT. Data are the 
mean for four independent experiments +/- SD.  
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Fig. 4: Transcript levels of proteasome subunits in HSF-deficient iMEFs and HSF2 
rescued iMEFs. WT or HSF-deficient iMEFs (Hsf1-/-. Hsf2-/- and Hsf1-/- & Hsf2-/-) were 
plated and total RNA were extracted the day after. Relative basal expression of two 
proteasomal subunits Psmb5 (A) and Psmd10 (B) were assessed by real time PCR and 
normalized using three reference genes Gapdh, Hprt1 and Tbp. Transcript levels in HSF-
deficient cells were presented as relative value to WT. Data are the means for four 
independent experiments +/- SEM. (Student’s test compared to WT cells. * p<0.05, ** 
p<0.01, *** p<0.001). For rescue experiments cells were transfected with PCR3.1 as control 
vector (white histogram) or PCR3.1 expressing HSF2 (black histogram). Three independent 
stable clones of each transfection were selected (cl 1, 2, 3 for control vector transfection and 
cl 4, 5, 6 for HSF2 transfection). Psmb5 (C) and Psmd10 (D) expression level were measured 
by real-time PCR in each clone and in WT cells (grey histogram). Transcript levels in each 
stable clone and in WT cells were presented as relative value to PCR3.1 cl 1 for three 
independent experiments +/- SEM. Data were analyzed with qBase software.  
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Fig. 5: Stabilization of p53 in HSF2-deficient cells. (A) Untreated immortalized Mouse 
Embryonic Fibroblast (iMEFs) derived from WT or knock-out Hsf1 and/or Hsf2 mice (Hsf1-/-, 
Hsf2-/- and Hsf1-/- & Hsf2-/-) were analyzed by Western immunoblotting using antibodies 
against p53 and β-actin as control. (B) p53 gene expression was compared in WT, Hsf1-/-, 
Hsf2-/- and Hsf1-/- & Hsf2-/-  iMEFs, by real time RT-PCR. Data were normalized by three 
reference genes Gapdh, Hprt1 and Tbp and analyzed using qBase software. Histograms 
represent relative expression means +/- SD of four independent experiments. (C) WT, Hsf1-/- 
and Hsf2-/- iMEFs were grown and metabolically labeled with L-[35S] methionine for pulse-
chase study. Labeled proteins were immunoprecipitated using anti-p53 antibody and subjected 
to denaturing electrophoresis. Lysate 35S was used as loading and 35S incorporation control. 
(D) Primary MEFs from WT, Hsf1-/- and/or Hsf2-/- animals were treated with DMSO (cont) or 
with 1 µM of MG132 for 16 h. Protein extracts were prepared and p53 western blotting was 
realized. β-actin was used as loading control. 
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Supplemental data 
 
Table primers sequences 
Gene name and symbol Forward primer Reverse primer 
Heat shock protein 70kDa 
(Hsp70) GGCCACATTGTTGATACATGC CTACAGTGCAACCACCATGC 
Heat shock protein 27kDa 
(Hsp27) AATGGTGATCTCCGCTGACT CCTCTTCCCTATCCCCTGAG 
Proteasome subunit alpha-
type 1 (Psma1) GATCACCGAACCGTAGTTGG CAACTGTTGCTGAACCTTGC 
Proteasome subunit alpha-
type 5 (Psma5) CCCCACTAATGGAGCCTAGC AGAGCCAGATTGGACACAGC 
Proteasome subunit beta-type 
2 (Psmb2) TGACTCTCAGCATCCTTGACC GTTAGGAGTCCCGCTTAGGG 
Proteasome subunit beta-type 
4 (Psmb4) ACTACAAAGATGCCCGTTCG TTGAGCCAGCTACAGTCACG 
Proteasome subunit beta-type 
5 (Psmb5) GATCAACCCGTACCTTCTGG CGAGATGCGTTCCTTATTGC 
26S protease regulatory 
subunit 6B (Psmc4) CGAGGTGTCCTCATGTATGG GCAGGTGCATTCTCCTTAGC  
26S protease regulatory 
subunit 8 (Psmc5) TAACAAGGTGGACCCTTTGG TAGAGCAGGACTCCCTTTGG 
26S proteasome non-ATPase 
regulatory subunit 3 (Psmd3) CTTTTGAACCTCCTGCTTCG AGCTGGATAGCCTTGATTCG 
26S proteasome non-ATPase 
regulatory subunit 4 (Psmd4) CCTATTCTGGCTGGTGAAGG GTAGCAATTCCAGCCTCAGC 
26S proteasome non-ATPase 
regulatory subunit 10 
(Gankyrin) (Psmd10) 
TGCACTCCACTCCATTATGC AGCATCGTAATGGTCCTTCG 
Cellular tumor antigen p53 
(Tp53) TGAACCGCCGACCTATCCTTA GGCACAAACACGAACCTCAAA 
Ubiquitin B  
(Ubb) AGTGACGAGAGGCTTTGTCC ACGAAGATCTGCATTTTGACC 
Ubiquitin C  
(Ubc) AGCCCAGTGTTACCACCAAG ACCCAAGAACAAGCACAAGG 
Glyceraldehyde-3-phosphate 
dehydrogenase (Gapdh) TGAAGCAGGCATCTGAGGG CGAAGGTGGAAGAGTGGGAG 
Hypoxanthine-guanine 
phosphoribosyltransferase 
(Hprt1) 
CCTAAGATGAGCGCAAGTTGAA CCACAGGACTAGAACACCTGCTAA
TATA box binding protein 
(TBP) GGCCTCTCAGAAGCATCACTA GCCAAGCCCTGAGCATAA 
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Flow cytometry analysis 
WT, Hsf1-/-, Hsf2-/- and Hsf1-/- & Hsf2-/- iMEFs were plated in 6 well-plate and treated with 1 
µM MG132 for 16 h. Cells were trypsined and labeled with Annexin-V FITC (Becton 
Dickinson Pharmigen, CA, USA) and 1 µg of 7-Aminoactinomycin D (7-AAD) (Sigma 
Aldrich, MO, USA) for 15 min at room temperature and at obscurity. Apoptosis was 
performed with FACScalibur flow cytometer (Becton Dickinson, NJ, USA) by analyzing 10 
000 events. Data analyses were performed using Cell Quest Pro software (Becton Dickinson, 
NJ, USA). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. S1: Representative flow cytometry analysis of cellular apoptosis after MG132 
exposure. WT, Hsf1-/-, Hsf2-/- and Hsf1-/- & Hsf2-/- iMEF were treated with DMSO (left panel) 
or with 1 µM of MG132 for 16 h (right panel). Then apoptosis level was assessed by flow 
cytometry using annexin-V fluorescein isothiocyanate (FITC) and 7-aminoactinomycin D (7-
AAD) labeling. A typical log fluorescence intensity of annexin V- FITC and 7-AAD plot with 
quadrant delimiting regions with distinct sub-populations of events is shown. Percentages of 
cells present in each phase were analyzed using Cell Quest Pro software and indicated on 
graph.  
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Analysis of Hsf2 expression in stable clone 
For the establishment of HSF2 stably transfected cells, Hsf2-/- iMEFs were co-transfected with 
a pIRES Hygro coding for Hygromycin B resistance and either with expression vector 
PCR3.1 or by PCR3.1 coding for HSF2α. Clones were selected in the medium described in 
materials and methods supplemented by 0.2 mg / ml of hygromycin B (Calbiochem, 
Germany). Hsf2 expression was measured at RNA level by RT-PCR and at protein level by 
HSF2 immunoblot. One million of each selected clone were plated into 10 cm plate and 
harvested after 24 h of culture. For RT-PCR, total RNA were extracted using Trizol reagent 
(Invitrogen Life Science, CA USA) according to manufacturer’s procedure. Then 5 µg of 
RNA were retrotrancribed using M-MLV RT (Invitrogen Life Science, CA USA). PCR was 
performed using Taq DNA polymerase (Qiagen, France) with 100 ng of cDNA and 500 nM 
of primers. Primers sequences used for Hsf2 are: 5’-CATGTCTAGTGCTGTCCAGC-3’ 
(forward primer) and 5’-GAGCTCATCGACTTCTATGG-3’ (reverse primer). Gapdh served 
as loading control. For HSF2 immunoblot, cells were treated with 1 µM of MG132 for 10 h 
and nuclear extracts were prepared with the nuclear extract kit (Active Motif, Belgium) in 
accordance with manufacturer’s procedure. 30 µg of protein were loaded and separated on 
polyacrylamide gel. Proteins were transferred on nitrocellulose membrane and HSF2 were 
revealed by an anti-HSF2 antibody (sc-13517) (Santa Cruz Biotechnology, CA USA). 
Ponceau staining were shown as loading control. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. S2: Assessment of HSF2 expression in Hsf2α stably transfected Hsf2-/- iMEFs. 
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RT-PCR analysis of Hsf2 expression (A) clearly showed that clones stably transfected with 
Hsf2α expressed this transcript whereas cells transfected with the expression control vector 
PCR3.1 did not. Slight expression differences between each clone could be the results of the 
number of insertion of Hsf2 or chromatin compaction in the insertion site. Expression of Hsf2 
in WT cells was realized as positive control and showed the two isoforms of Hsf2 α and β. 
HSF2 is a constitutive expressed protein and a constitutive degraded proteins. To detect this 
transcription factor cells must be treated with MG132 to stabilize HSF2. HSF2 immunoblot 
(B) in cells transfected with PCR3.1 did not show the presence of HSF2 whereas in cells 
transfected with HSF2 a strong expression was detect in clone 4 and 5. In clone 6 HSF2 
expression was found less important compared to other clones. HSF2 immunoblot in WT cells 
served as positive control. 
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Formaldehyde Assisted Isolation of Regulatory Elements (FAIRE) 
WT, Hsf1-/- and Hsf2-/- iMEFs were grown in 15 cm plates to 60-70% confluence. Then cells 
were cross-linked with 1% formaldehyde for 10 min at room temperature. Formaldehyde was 
poured off and cells were incubated with 125 mM glycine for 5 min at room temperature. 
iMEFs were rinsed with ice cold PBS and harvested. Cells were lysed with 1% SDS, 10mM 
EDTA and 50mM Tris-HCl pH 8.1 supplemented with protease inhibitor cocktail (Roche 
Applied Science, France) and sonicated for 14 min (30 s on / 30 s off cycles) using a 
Bioruptor (Diagenode) set up at the highest intensity. 20 µl of chromatin were taken as input. 
The soluble extracts were subjected to three consecutive phenol-chloroform isoamylic acid 
extractions to expand in open chromatin. To reverse cross-linking samples were incubated at 
65 °C overnight. Finally DNA was purified using Nucleospin Extract II (Macherey Nagel, 
Germany). Data were analyzed by real time PCR with 0.5 µl of inputs and 3 µl of chromatin 
subjected to phenol-chloroform extractions.  
Fig. S3: FAIRE-Real Time PCR analysis of chromatin at the transcription start site of 
Psmd10 and on clusterin HSE in WT, Hsf1-/- and Hsf2-/- iMEFs. Compaction of chromatin 
at the transcription start site of Psmd10 and one clusterin HSE was abritary fixed to 1 in WT 
cells and data obtained from HSF-deficient cells were expressed in relative FAIRE 
enrichment to WT cells. Mean for three experiments +/-SD (* p<0.05 Student’s t Test). Data 
obtained clearly showed that chromatin was more compacted at the transcription start site of 
Psmd10 in HSF-deficient cells than WT iMEFs. 
 
